UroGen Pharma Ltd. (URGN)
NASDAQ: URGN · Real-Time Price · USD
11.91
+0.36 (3.12%)
Nov 22, 2024, 4:00 PM EST - Market closed
UroGen Pharma Employees
As of December 31, 2023, UroGen Pharma had 201 total employees, including 198 full-time and 3 part-time employees. The number of employees increased by 1 or 0.50% compared to the previous year.
Employees
201
Change (1Y)
1
Growth (1Y)
0.50%
Revenue / Employee
$444,592
Profits / Employee
-$574,020
Market Cap
502.60M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Auna S.A. | 14,958 |
Emergent BioSolutions | 1,600 |
Health Catalyst | 1,300 |
Pacific Biosciences of California | 796 |
Pharming Group | 382 |
Esperion Therapeutics | 240 |
Alumis | 109 |
Korro Bio | 102 |
URGN News
- 6 days ago - Undercovered Dozen: Aurora Cannabis, FREYR Battery, Royalty Pharma, Talos Energy + - Seeking Alpha
- 9 days ago - UroGen Pharma: Choice Based On Near Term High Value PDUFA - Seeking Alpha
- 16 days ago - UroGen Pharma Ltd. (URGN) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 16 days ago - UroGen Pharma Reports 2024 Third Quarter Financial Results and Business Highlights, Including the Potential Launch of UGN-102 in 2025 - Business Wire
- 17 days ago - UroGen Pharma to Present at the Guggenheim Securities Healthcare Innovation Conference - Business Wire
- 23 days ago - UroGen Pharma to Report Third Quarter Financial Results on Wednesday, November 6, 2024 - Business Wire
- 25 days ago - ENVISION Trial Results Published in the Journal of Urology Report 82.3% Duration of Response 12 Months after Achieving Complete Response for UGN-102, Potentially First FDA-Approved Non-Surgical Treatment for LG-IR-NMIBC - Business Wire
- 5 weeks ago - UroGen Announces FDA Acceptance of its New Drug Application for UGN-102 - Business Wire